Compositions and Methods Related to CRISPR Targeting

• US 20150098954A1
• Filed: 10/08/2013
• Published: 04/09/2015
• Est. Priority Date: 10/08/2013
• Status: Abandoned Application

• Current Assignee: Elwha LLC (Intellectual Ventures LLC)
• Original Assignee: Elwha LLC (Intellectual Ventures LLC)
• Inventors: Hyde, Roderick A., Kindsvogel, Wayne R., Wood, Lowell L.
• Application Number:
  US14/048,283
• Publication Number:
  US 20150098954A1
• Time in Patent Office: Days
• US Class Current: 424/184.1
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: C12N 15/907 in mammalian cells
• CPC Class Codes: C12N 2750/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2830/002 inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Abstract

Disclosed herein include embodiments related to addition, deletion, or modification of DNA, RNA, or protein in a subject. In an embodiment, the DNA, RNA, or protein is endogenous. In an embodiment, the DNA, RNA, or protein is exogenous. Further embodiments relate to computerized systems for assisting in the disclosed methods.

Claims

1. A composition comprising:

an non-integrating epichromosomal vector encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA;

one or more target sequences, and

one or more condition-inducible promoters.

2. The composition of claim 1, wherein the condition-inducible promoter includes at least one of a pathogen-inducible promoter, a pH-inducible promoter, a temperature-inducible promoter, a magnetic-inducible promoter, light-inducible promoter, or a chemical-inducible promoter.

14. The composition of claim 1, wherein the cas gene includes one or more of Cas3 or Cas9.

15. The composition of claim 1, wherein the non-integrating epichromosomal vector includes at least one of non-integrating adeno-associated virus vector, non-integrating Epstein Barr virus vector, non-integrating lentiviral vector, non-integrating Sendai virus vector, or any hybrid thereof.

16. The composition of claim 1, wherein multiple CRISPR guide RNA sequences are encoded in the vector.

17. The composition of claim 1, wherein the one or more target sequences include at least one of a pathogen sequence, auto-antigen, somatic cell mutation, allergen, transplant antigen, or auto-reactive lymphocyte receptor or receptor component.

18. The composition of claim 17, wherein the auto-reactive lymphocyte receptor or receptor component includes an auto-reactive variable beta chain receptor component for a T cell or a B cell.

19. The composition of claim 1, further including one or more insertion sequences encoded in the vector.

20. The composition of claim 1, wherein each of the one or more target sequences is included as part of a suite with each target sequence under control of its own promoter.

21. The composition of claim 20, wherein multiple suites of at least one target sequence are included as part of the same vector.

22. The composition of claim 1, further including one or more externally activated control sequences.

23. The composition of claim 22, wherein the one or more externally activated control sequences control transcription of one or more caspases encoded by the vector.

3-13. -13. (canceled)

24. (canceled)

25. A method, comprising:

administering to a host cell,

a non-integrating epichromosome vector

encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA;

one or more target sequences, and

a condition-inducible promoter.

32. The method of claim 25, wherein the cell includes a hematapoeitic cell.

33. The method of claim 32, wherein the hematapoetic cell includes at least one of a precursor blood cell, or a differentiated blood cell.

34. The method of claim 32, wherein the hematapoetic cell includes a lymphocyte.

26-31. -31. (canceled)

35. A method, comprising:

inhibiting a pathogen by administering to a host cell,

a non-integrating epichromosome vector

encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA;

one or more target sequences of a pathogenic antigen against which an immune response is desired, and

a condition-inducible promoter.

36-37. -37. (canceled)

38. A method, comprising:

reducing or eliminating an immune response to an antigen against which an immune response is not desired by administering to a host cell,

a non-integrating epichromosome vector encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA;

one or more target sequences of the antigen against which an immune response is not desired, and

a condition-inducible promoter.

39. The method of claim 38, wherein the antigen includes one or more of an auto-antigen, an allergen, or a transplant antigen.

40. A method, comprising:

in vivo genetic editing by administering to a host cell,

a non-integrating epichromosome vector encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA;

one or more target sequences for desired editing, and

a condition-inducible promoter.

41-42. -42. (canceled)

43. A method, comprising:

reducing or eliminating an immune response to an antigen against which an immune response is not desired by administering to a host lymphocyte cell,

a non-integrating epichromosome vector encoding at least one of a cas gene, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs), or CRISPR guide RNA; and

one or more target sequences of at least one lymphocyte receptor variable chain sequence against which an immune response is not desired.

44. The method of claim 43, wherein the at least one lymphocyte receptor variable chain sequence includes at least one T cell receptor variable chain beta sequence.

45. The method of claim 43, wherein the at least one T cell receptor variable chain beta sequence includes one or more sequences corresponding to auto-antigens.